Eli Lilly launches lower-priced version of weight loss drug Zepbound


Full story

With weight loss drugs in high demand, Eli Lilly is significantly lowering the price of its drug Zepbound in a move to make it easier for people to get their hands on it. The drugmaker is dropping the prices for its two lowest doses of the weight loss medication. However, it will only come in single-dose vials that users have to load into a syringe themselves.

Zepbound and other similar weight loss drugs usually come in self-contained injector pens.

QR code for SAN app download

Download the SAN app today to stay up-to-date with Unbiased. Straight Facts™.

Point phone camera here

Under the new pricing plan, a month’s supply of the lowest dose, 2.5 mg, will cost $399 dollars, while a month’s supply of the 5 mg dose will cost $549. That is a big difference from a monthly list price of $1,059, regardless of the dosage.

Use of tirzepatide, the active ingredient in Zepbound, to lose weight has skyrocketed in popularity, leading to shortages. It also led some people who cannot get a prescription or whose insurance does not cover it to use versions made by compounding pharmacies, which can be dangerous.

The new single-dose vials will only be available through the company’s telehealth platform, LillyDirect, to those who pay out of pocket.

Tags: , , , , , , , , ,

SAN provides
Unbiased. Straight Facts.

Don't just take our word for it.


Certified balanced reporting

According to media bias experts at AllSides

AllSides Certified Balanced May 2025

Transparent and credible

Awarded a perfect reliability rating from NewsGuard

100/100

Welcome back to trustworthy journalism.

Find out more

SAN provides
Unbiased. Straight Facts.

Don't just take our word for it.


Certified balanced reporting

According to media bias experts at AllSides

AllSides Certified Balanced May 2025

Transparent and credible

Awarded a perfect reliability rating from NewsGuard

100/100

Welcome back to trustworthy journalism.

Find out more

Media landscape

Click on bars to see headlines

51 total sources

Key points from the Center

No summary available because of a lack of coverage.

Report an issue with this summary

Powered by Ground News™